January 29-31, 2019 | San Francisco

Day One
Wednesday 30th January, 2019

Day Two
Thursday 31st January, 2019

Chair’s Opening Remarks

Advances in Senolytic Approaches for Disease of Aging


  • Understanding aging as a multi-mechanism process
  • Addressing senescence as a driver of features of aging
  • Exploring senolysis as a means to blunt specific diseases
  • Developing senolytic medicines for age-related diseases

Aging & Drug Discovery – The Next Frontiers in Senolytics

  • Judith Campisi Professor, Buck Institute for Research on Aging & Lawrence Berkeley National Laboratory


  • Exploring how cellular senescence is invoked by physiological signals and stressful stimuli, and can be beneficial or detrimental, and entails a tripartite phenotype (essentially irreversible block to cell proliferation, multifaceted senescence-associated secretory phenotype (SASP), and resistance to apoptosis)
  • Establishing how it is now clear that senescent cells increase during aging and in response to stress and are causal drivers of several age-related pathologies, ranging from neurodegeneration to cancer
  • Discussing the strengths and weaknesses of these approaches, and strategies for improving their efficacy

Keynote Panel: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities

  • Aubrey de Grey CSO, SENS Foundation & VP of New Technology Discovery, AgeX Therapeutics
  • Judith Campisi Professor, Buck Institute for Research on Aging & Lawrence Berkeley National Laboratory
  • Nir Barzilai Professor & Director, Institute for Aging Research, Albert Einstein College of Medicine


  • Exploring what we know and what we still don’t know about the aging process
  • Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions
  • Analyzing the current R&D landscape for anti-aging therapeutics
    • Key challenges in discovery and progression of pipelines
    • Greatest promises for healthspan improvement
    • Addressing and dealing with pseudo-science and off label products
  • Are gaps in our understanding of the basic biology of aging in model organisms, as well as in humans, preventing the development of new approaches?
  • Discussing the recent breakthroughs and the growing interest in this space – attracting funding/partnerships, important learnings to date and perspectives on future directions

Speed Networking Session

Morning Refreshments

Developing Innovative Therapeutic Approaches Targeting Age-Related Diseases – PART 1: Senescence

Influencing Splicing Factor Expression to Target Senescence

  • Lorna Harries Associate Professor in Molecular Genetics, University of Exeter Medical School


  • Analyzing the unclear molecular basis for human aging being a heterogeneous condition, where some succumb to age-related diseases at a relatively early age
  • Exploring cellular plasticity and how it is determined predominantly by alternative splicing by which 95% of our genes produce more than one transcript in a regulated fashion
  • Determining that transcripts involved in these processes are amongst the most deregulated mRNAs during human ageing in population studies, and also in fibroblasts that have undergone replicative senescence in vitro
  • Treating senescent primary human fibroblasts with small molecules that influence splicing factor expression to rescue multiple features of cellular senescence in aged human cells – determining how small molecule modulators of splicing factor expression may represent promising novel anti-degenerative therapies in the future

The Challenge of Developing Novel Senolytic Medicines


  • Exploring cellular senescence: fibrosis and cancer
  • Describing our approach to design senolytic medicines
    • STX077 targeted therapy: a versatile drug delivery system
    • STX255 immuno-senescence approach

The Role of Senescent Cells in Neurodegeneration – New Data

  • Darren Baker Assistant Professor,Departments of Pediatric & Adolescent Medicine & of Biochemistry & Molecular Biology, Mayo Clinic


  • Addressing the accumulation of senescent cells in tissues in prematurely aged mice
  • Eliminating senescent cells to alleviate tissue degeneration and extend life in normal mice
  • Senescent cells contribute to neurodegenerative disease (and other diseases of aging)

Lunch & Networking

A Novel Apoptotic Gene Therapy Approach for Systemic Senolysis


  • Overviewing Oisin’s LNP Gene Therapy Platform for selective ablation of senescent cells
  • Discussioning recent biodistribution and efficacy results in small and large animal models
  • Updating on recent longevity data in animal models
  • Overviewing clinical development plans

Developing Innovative Therapeutic Approaches Targeting Age-Related Diseases – PART 2

Therapeutics from Plasma: Targeting Chronokines for Disorders of Aging


  • Exploring novel insights into aging through the plasma proteome
  • Detailing on how functional drivers in plasma provide peripheral targets for CNS disorders
  • Establishing a multimodal therapeutic approach for age-related disorders
  • Rapid clinical advancement of highly differentiated therapeutics

Mitochondrial Dysfunction & Aging: Elamipretide as a Potential Intervention


  • Understanding how mitochondrial dysfunction is complicit in multiple age-related diseases
  • Demonstrating the potential to impact aging by improving mitochondrial function in preclinical studies
  • Introducing Elamipretide, a novel, first in class mitochondrial therapeutic in clinical development
  • Exploring how multiple preclinical studies support elamipretide as a potential therapy for age-related diseases

Supporting Discovery in Aging Research With Big Data

Hacking Aging: A Data-Driven Approach to Healthy Life Extension


  • Discussing physical kinetics of aging for systematic discovery of aging biomarkers and anti-aging targets
  • Exploring the discovery of aging biomarkers in longitudinal blood data and physical records from wearable devices
  • Analyzing time scales involved in aging dynamics: implications for preclinical research and clinical trials
  • Presenting an interim report: plasma proteome as the target for therapeutic interventions against aging; can we slow down aging in mice by hitting targets discovered in longitudinal human plasma proteomics?

Afternoon Refreshments & Networking

AI-Powered End-to-End Pipelines for Drug Discovery


  • Detailing on how artificial techniques such as deep learning, reinforcement learning (RL), and generative adversarial networks (GANs) present opportunities for studying the biology of aging on the many levels and generating hypotheses for interventions
  • Developing multi-modal predictors of age using a variety of data types ranging from imaging and common blood tests to transcriptomic and microbiomic data – pioneered the applications of modern AI to aging research
  • Using GANs to generate synthetic patient data and identify novel targets and causal graphs
  • Exploring the most recent advances in modern and nex-gen AI for biology and chemistry conducted in the labs of Insilico Medicine worldwide

Data-driven Approaches to Identifying Circulating Factors That Drive Aging


  • Exploring how omics data enables us to study aging directly in humans, rather than less translationally relevant model systems
  • Focusing on omic phenotyping of human aging cohorts that have decades of follow-up EHRs
  • Integrating multiple data modalities for data-driven discovery of key aging targets

Prioritizing Drugs & Targets in Aging Research


  • Exploring network pharmacology and machine learning approaches applied to lifespan-extending compounds
  • Presenting DrugAge, a curated database of lifespan-extending drugs and compounds, and its data analysis
  • Providing insights into lifespan-extending compounds and the genes and pathways they target – identifying and prioritizing further compounds with potential life-extending properties, which we validated experimentally

Chair’s Closing Remarks